The double-blinded, placebo controlled trial is evaluating the use of the monoclonal antibody therapy designed to block chronic inflammation associated with malignant tumor growth. According to the company,
The approval was given after reviewing results from a large clinical program which included over ten multinational clinical trials and more than 13,000 adults with T2D. The Phase
Darinaparsin is a new mitochondrial-targeted agent under development for the treatment of several hematologic and solid cancers. As part of the amended and restated deal, Solasia secured exclusive
CRT 001 (xamoterol fumarate), a selective partial agonist of the beta-1 adrenergic receptor (B1-ADR), is the lead drug candidate in the portfolio acquired by the company. B1-ADR is
The company’s latest innovation provides patient self administration of drugs and biologics formulated as powders for systemic nasal, nose-to-brain, ophthalmic, sublingual and buccal routes of administration. Mystic president
In this trial, the company will evaluate the efficacy and safety of 1% LE-MPP and 0.25% LE-MPP dosed four times daily in patients having measurable intraretinal or subretinal
According to the company, Iluvien (190 micrograms intravitreal implant in applicator) is a sustained release intravitreal implant, which has a therapeutic effect of up to 36 months. The
Under the deal, Anika will receive product payment and royalty revenues from the sale of the product by Medline. Hyalomatrix is a biologically-derived matrix for in-growing cells, and
Dalbavancin will be commercialized in Italy, Spain, Poland, Portugal, many Eastern European countries, Russia, Turkey and Commonwealth of Independent States. As part of the deal, Durata will receive
The company has entered into an agreement with Sandoz Canada, pursuant to which the latter will produce, use, sell, market and distribute Olanzapine injection in Canada. InnoPharma president
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.